Biogen Idec to Present at the Cowen & Company 29th Annual Healthcare Conference

March 10, 2009 • Corporate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation and subsequent breakout session at the Cowen & Company 29^th Annual Healthcare Conference will be webcast live via the internet, on Tuesday, March 17^th at 9:30 a.m. ET. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com).

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

Contact:

Biogen Idec, Inc.
Rob Jacobson
Investor Relations
617-679-2812

May 13, 2021

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

As part of the agreement, Biogen will leverage Envisagenics’ AI platform with the goal of better understanding Central Nervous System diseases CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance

May 12, 2021

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated